In this long-form post published on LinkedIn Pulse and titled “Accelerating Braintech Innovation”, Einat Katzenell of Katzenell Dimant raintech doesn’t fit the common rubric.
I had the pleasure of working with Einat and providing Editorial Services for this piece.
Einat Katzenell is the Founding Partner of Katzenell Dimant and provides strategic and practical legal advice to hi-tech, life sciences and biotechnology entrepreneurs, investors, early stage and mature companies, academic institutions and business initiatives.
From the post: “Accelerating Braintech Innovation“:
“While other areas of high technology categorically take a B2B or B2C approach to marketing, Braintech doesn’t quite fit the common rubric. Consider the identity of your customers (the who) and the means by which they’re going to pay for your product (the how) – it’s plain to see that neurotechnology is in a class of its own.
Resolving the who and how issues at the very early stages of development is critical, because even though achieving scientific validation is fantastic – proving something works doesn’t in and of itself mean that it can be commercialized.
Imaging, cranial stimulation, implant technologies, cranial surface measurements, cell therapy and brain chemistry pharmaceuticals are some of the current technologies available on the market, and for the most part are used in medical institutions, specialized clinics, universities and research centers, and ultimately paid for by the insurance companies.”
Link to the full post